161 related articles for article (PubMed ID: 38661301)
41. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
Miyamoto S; Suzuki T
Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
[TBL] [Abstract][Full Text] [Related]
42. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
[TBL] [Abstract][Full Text] [Related]
43. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
44. The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.
Antinori A; Bausch-Jurken M
J Infect Dis; 2023 Aug; 228(Suppl 1):S4-S12. PubMed ID: 37539764
[TBL] [Abstract][Full Text] [Related]
45. Coronavirus disease 2019 vaccination in transplant recipients.
Eberhardt CS; Balletto E; Cornberg M; Mikulska M
Curr Opin Infect Dis; 2021 Aug; 34(4):275-287. PubMed ID: 34074880
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness of COVID-19 vaccines against severe outcomes in cancer patients: Real-world evidence from self-controlled risk interval and retrospective cohort studies.
Lee HE; Jeong NY; Park M; Lim E; Kim JA; Won H; Kim CJ; Park SM; Choi NK
J Infect Public Health; 2024 May; 17(5):854-861. PubMed ID: 38554591
[TBL] [Abstract][Full Text] [Related]
47. Incidence of breakthrough infections after COVID-19 vaccination among the COVID-19 vaccine recipients at a Tertiary Care Hospital in Srinagar.
Fazili A; Ain SN; Shah RJ; Raja FN; Farhat D; Nazir I
Indian J Public Health; 2023; 67(2):305-308. PubMed ID: 37459029
[TBL] [Abstract][Full Text] [Related]
48. Risk of breakthrough SARS-CoV-2 infection and clinical outcomes among vaccinated patients with type 2 diabetes.
Bea S; Choi A; Kim JH; Cho YM; Choi WS; Jung J; Shin JY
Diabetes Obes Metab; 2023 Sep; 25(9):2734-2742. PubMed ID: 37312652
[TBL] [Abstract][Full Text] [Related]
49. COVID-19 Breakthrough Infections in Vaccinated Kidney Transplant Recipients.
Zhang X; Weng R; Liu F; Xie Y; Jin Y; Li Q; Huang G; Chen J; Wang J; Shen H; Fu H; Mao J
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423007
[TBL] [Abstract][Full Text] [Related]
50. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.
Murray SM; Pose E; Wittner M; Londoño MC; Schaub G; Cook J; Dimitriadis S; Meacham G; Irwin S; Lim Z; Duengelhoef P; Sterneck M; Lohse AW; Perez V; Trivedi P; Bhandal K; Mullish BH; Manousou P; Provine NM; Avitabile E; Carroll M; Tipton T; Healy S; Burra P; Klenerman P; Dunachie S; Kronsteiner B; Maciola AK; Pasqual G; Hernandez-Gea V; Garcia-Pagan JC; Lampertico P; Iavarone M; Gines P; Lütgehetmann M; Schulze Zur Wiesch J; Russo FP; Barnes E; Marjot T;
J Hepatol; 2024 Jan; 80(1):109-123. PubMed ID: 37863203
[TBL] [Abstract][Full Text] [Related]
51. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
[TBL] [Abstract][Full Text] [Related]
52. COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization.
Stroffolini T; Ciancio A; Federico A; Benigno RG; Colloredo G; Lombardi A; Niro GA; Verucchi G; Ferrigno L; Gioli F; Marignani M
Dig Liver Dis; 2023 Mar; 55(3):316-321. PubMed ID: 36529636
[TBL] [Abstract][Full Text] [Related]
53. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness.
Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Weng C
medRxiv; 2021 Oct; ():. PubMed ID: 34642696
[TBL] [Abstract][Full Text] [Related]
54. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis.
Mehrabi Nejad MM; Moosaie F; Dehghanbanadaki H; Haji Ghadery A; Shabani M; Tabary M; Aryannejad A; SeyedAlinaghi S; Rezaei N
Eur J Med Res; 2022 Feb; 27(1):23. PubMed ID: 35151362
[TBL] [Abstract][Full Text] [Related]
55. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
56. Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
Subramanian V
J Infect Dis; 2023 Aug; 228(Suppl 1):S34-S45. PubMed ID: 37539762
[TBL] [Abstract][Full Text] [Related]
57. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
58. The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
Maeda M; Murata F; Fukuda H
Vaccine; 2024 Mar; 42(7):1542-1548. PubMed ID: 38320932
[TBL] [Abstract][Full Text] [Related]
59. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
60. A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection.
Dogra P; Schiavone C; Wang Z; Ruiz-Ramírez J; Caserta S; Staquicini DI; Markosian C; Wang J; Sostman HD; Pasqualini R; Arap W; Cristini V
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37227783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
